A Single-arm, Multi-center, Phase Ib/II Study of Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients (Xplore Trial)

  • End date
    Feb 28, 2026
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 28 October 2022


This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to evaluate the safety, tolerability, and efficacy of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated EBV-positive diffuse large B-cell lymphoma (DLBCL) patients.


This is a prospective, single-arm, multi-center, phase Ib/II clinical trial to explore the maximum tolerated dose (MTD) of selinexor when combined with R-CHOP regimen for untreated EBV-positive DLBCL patients.

Phase Ib study:

Selinexor will be given orally at two different doses (40mg qw, and 60mg qw ) and combined with the R-CHOP regimen from the second cycle based on the "3+3" principle.

In the induction therapy period, 6 cycles of R-CHOP regimen and 2 cycles of rituximab in combination with selinexor are planned.

The dose limited toxicity (DLT) will be evaluated after the first cycle of selinexor in combination with R-CHOP.

Phase II study:

The phase II study of selinexor at recommended phase II dose (RP2D) dose level combined with R-CHOP regimen was conducted to explore the efficacy and safety of the combined regimen.

After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted.

Condition EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Treatment Selinexor, R-CHOP Protocol
Clinical Study IdentifierNCT05577364
SponsorSun Yat-sen University
Last Modified on28 October 2022


Yes No Not Sure

Inclusion Criteria

Subjects fully understand and voluntarily participate in this study and sign informed consent
Age ≥18, ≤70 years, no gender limitation
Histologically confirmed diagnosis of EBV-positive diffuse large B-cell lymphoma (DLBCL) (more than 50% of tumor cells are positive with EBV encoded small RNAs (EBERs) in situ hybridization were considered EBERs positive)
Untreated patients, except for the short-time use of prednisone for controlling tumor-induced symptoms (no more than 30mg/d (or other equivalent amounts of other glucocorticoids), no more than 7 days)
There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography/computed tomography (PET/CT) or CT and/or MRI, intranodal lesions with long diameter >1.5cm, and short diameter >1.0cm, or extranodal lesions with long diameter > 1.0 cm
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
Expected survival ≥ 3 months
Adequate function of bone marrow
White blood cell ≥3.0×10E9/L, absolute neutrophil count ≥1.5×10E9/L Platelet
≥100×10E9/L (Bone marrow invasive patient≥75×109/L) Hemoglobin≥ 90g/L No
granulocyte growth factor, platelet, or red blood cell transfusions were
received within 14 days prior to examination
Adequate function of the liver and renal
Total bilirubin≤2×upper limit of normal (ULN) (patients with liver invasion or
Gilbert syndrome ≤5×ULN) Alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) ≤2.5×ULN (patients with liver invasion ≤5×ULN) Serum
creatinine ≤1.5×ULN or creatinine clearance rate ≥60 mL/min
The patients agree to take effective contraceptive measures during the study period and till 12 months after the last administration of the study treatment

Exclusion Criteria

EBV-positive DLBCL combined with other types of lymphoma. Transformed DLBCL
EBV-positive DLBCL with central nervous system invasion
The patients had previously received XPO1 inhibitors, such as selinexor and so on
The patients have contraindications to any drug in the combined treatment
The major surgery is performed within 4 weeks before enrollment, except for diagnosis
There are any life-threatening diseases, medical conditions or organ system dysfunction that the investigator believes may affect the safety or compliance of patients
Heart function and disease meet one of the following conditions
Heart failure with the classification of New York Heart Association heart function of grade II
A history of unstable angina pectoris
A history of myocardial infarction within the past 1 years
Patients with clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
A history of other malignant tumors within the past 5 years (except the cured cervical
cancer and basal cell carcinoma of the skin)
Patients with active bleeding
Uncontrolled infection exists within 7 days before treatment and parenteral antibiotics, antiviral drugs or antifungal drugs are needed; However, preventive use of these drugs (including parenteral anti-infective drugs) is allowed
Patients with chronic active hepatitis B or active hepatitis C. If the background hepatitis B Surface Antigen (HBsAg) and/or hepatitis B core Antibody (HBcAb) or hepatitis C Virus (HCV) antibody are positive, the further determination for Hepatitis B Virus (HBV) DNA (no more than 2500 copies /mL or 500 IU/mL) and HCV RNA (no more than the lower limit of the assay) can be included. The patients with HBsAg and/or HBcAb positive need to receive anti-HBV drugs
Patients with the infection of human immunodeficiency virus (HIV) and/or acquired Immunodeficiency syndrome
Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug
Pregnant and lactating women, and subjects of childbearing age who do not want to use contraception
Mentally ill persons or persons unable to obtain informed consent
The investigators think that the patient is not suitable for the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note